newsfilter
← Latest News
GlobeNewswire·

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM) Dialogue continues with regulatory agencies concerning CYAD-101-002 Phase 1b t